RWT

REDWOOD TRUST (RWT) Prices $205M of 7.00% Convertible Notes Due 2030

The mortgage REIT signed an indenture for up to $205 million of 7.00% convertible senior notes maturing in 2030, convertible at about $4.90 a share.

Redwood Trust (RWT) has entered into an indenture dated September 15, 2026 covering its 7.00% Convertible Senior Notes due 2030, issued initially in an aggregate principal amount not to exceed $205,000,000. The filing was disclosed in an 8-K flagging a material agreement, a new financial obligation and an unregistered sale of equity securities.

A utility-scale solar farm of the type planned under the Tadaa and Kainan partnership.

TREASURE GLOBAL (TGL) Unit Joins $367M, 360 MW Malaysian Solar Farm Project

Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.

A natural gas wellhead of the kind found across Pennsylvania's Marcellus shale.

ALPHA COMPUTE (ALP) Buys 300 Acres of Pennsylvania Gas Land for $5.5M

Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.

Palisade Bio is developing an oral prodrug aimed at inflammatory bowel disease.

FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease

Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.

PDS Biotechnology is seeking a partner to fund Phase 3 development of its HPV16-targeted immunotherapy PDS0101.

PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival

VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.

Read more

TREASURE GLOBAL (TGL) Unit Joins $367M, 360 MW Malaysian Solar Farm Project

ALPHA COMPUTE (ALP) Buys 300 Acres of Pennsylvania Gas Land for $5.5M

FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease

PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival